The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes: DPP-4 inhibition and glycaemic control
Abstract
The aim of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes who have inadequate glycaemic control on diet and exercise. In a randomised, double-blind, placebo- and active-controlled study, 743 patients with type 2 diabetes and a mean baseline HbA(1c) of 7.9% were randomised to receive one of six treatments for 12 weeks: placebo, sitagliptin 5, 12.5, 25 or 50 mg b.i.d., or glipizide 5 mg/day (electively titrated up to 20 mg/day). At week 12, treatment with sitagliptin at all doses tested led to a significant (p < 0.001) reduction in HbA(1c) relative to placebo, with the largest reductions occurring in the 50-mg b.i.d. group. The placebo-subtracted differences in HbA(1c) for the sitagliptin dose groups ranged from -0.38% to -0.77% in a dose-dependent manner, and -1.00% in the glipizide group. Sitagliptin also produced significant reductions in fasting plasma glucose and mean daily glucose across the dose range studied. Sitagliptin treatment was well tolerated and resulted in no significant weight change relative to placebo. There was a modest weight gain observed with glipizide treatment relative to placebo. Hypoglycaemia adverse experiences were reported with the highest incidence in the glipizide group (17%) compared with the placebo (2%) or sitagliptin groups (0-4%, not dose-dependent). In summary, in this study sitagliptin improved glycaemic control, with 50 mg b.i.d. being the most effective dose, and was generally well-tolerated in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Biological actions and therapeutic potential of the glucagon-like peptides
Drucker, D. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.31068 · Cited by 500
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
Cited by
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308
Williams-Herman, D., Engel, S. S., Round, E., Johnson, J., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-7 · Cited by 258
Vittone, F., Liberman, A., Vasic, D., Ostertag, R., Esser, M., Walcher, D., Ludwig, A., Marx, N., & Burgmaier, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2582-5 · Cited by 97
Metadata
- Authors
- Scott, R., Wu, M., Sanchez, M., & Stein, P.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2006-12-05
- Volume
- 61
- Issue
- 1
- Pages
- 171-180
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W1585447752
- Cited by
- 260
- References
- 15
- FWCI
- 19.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes: DPP-4 inhibition and glycaemic control. https://app.cochat.ai/papers/10.1111/j.1742-1241.2006.01246.x
- The paper
- Scott, R., Wu, M., Sanchez, M., & Stein, P. (2006). Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes: DPP-4 inhibition and glycaemic control. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2006.01246.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.